Subject: Drug [email-masked] 22 September 2006

From: "Drug Discovery Alert"<[email-masked]>
Date: Fri, 22 Sep 2006 11:23:47 -0400 (EDT)

|

| nature.com | | about npg | | [email-masked] | | naturejobs | | natureevents | | help | | site index |

|

| SEARCH SITE | | | | | | |

| Table of Contents

22 September 2006 Issue

Horizon Symposia

News

Research highlights

Research & reviews

Market analysis

Naturejobs drug discovery

Subscribe now

This eTOC Alert has been sponsored by Roche Applied Science

Nature Protocols - Recipes for Researchers
Discover a unique combination of established and peer-reviewed experimental Nature Protocols and FREE user-generated content in our Protocols Network. The two streams create a dynamic resource for scientists, in all areas of research. Visit Nature Protocols to submit your protocols and sign up for Nature Protocols E-alerts.

www.natureprotocols.com

| |
| News |

Health agency backs use of DDT against malaria
Much-maligned pesticide returns to the front line.

| |

Agency accused of 'illusion of integrity'
NIH grilled over handling of ethics breaches.

| |

Medicine: Sleep it off
We've been told to eat less and move more to battle the growing obesity epidemic. But could getting more shuteye also be a way to fight the fat?

| |

Review uncovers new killer drug
Common painkiller may induce heart attacks.

| |
more news

| Research highlights |

Informatics: Exploring pharmacological space
Integration of medicinal chemistry efforts provides a improved vision of druggability.

| |

Targeted therapy: Stressed out hearts
Study provides heartache for Gleevec.

| |

Neurological disorders: Mind over machine
Using the mind to improve severe spinal cord injuries.

more research highlights

| Market analysis |

From the analyst's couch: Hepatitis C virus therapies
New treatments in the pipeline for the 'silent killer'.

| |

Fresh from the pipeline: Dasatinib
New kinase inhibitor for treating drug-resistant leukaemia.

more market analysis articles

| Research & reviews |

Targeting proteases: successes, failures and future prospects
The trials and tribulations creating protease inhibitors.

| |

Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras
RNAi can reach its target better with the help from an RNA friend.

| |

Divorcing ARF and p53: an unsettled case
How much do these two important proteins in cancer need each other?

| |

Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis
Apoptosis could be a new therapeutic target for inflammatory disorders.

more research & reviews

| Naturejobs drug discovery |

| |

Simon Campbell
The ex-research head of Pfizer discusses why bigger isn’t necessarily better for R&D productivity.

| |

Search for jobs in the field of Drug Discovery

Search for events in the field of Drug Discovery

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your current account at: www.nature.com/nams/svc/myaccount
(You will need to log in to be recognised as a nature.com registrant)

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscriptions department

For other enquiries, please contact our customer feedback department
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA

Nature's world-wide offices:
London • Paris • Munich • New Delhi • Tokyo • Melbourne
San Diego • San Francisco • Washington • New York • Boston

© 2006 Nature Publishing Group